Doxorubicin Cardiotoxicity Governed by Cardiac Microvascular Endothelial Pyroptosis and NLRP3 Inflammasome Assembly

Explore the molecular mechanisms of doxorubicin cardiotoxicity driven by cardiac microvascular endothelial pyroptosis, NLRP3 activation, and GSDMD cleavage.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Doxorubicin triggers microvascular endothelial collapse at 0.2–1.0 μM concentrations hours before cardiomyocyte troponin leakage manifests clinically [1][2].
  • 2
    Mitochondrial redox cycling produces superoxides and oxidized mitochondrial DNA that drive transcriptional priming and structural activation of the NLRP3 inflammasome [3][4].
  • 3
    Active Caspase-1 cleaves Gasdermin D at Asp275 to yield a 31 kDa N-terminal fragment that forms 10–14 nm oligomeric pores in endothelial membranes [5][6].
  • 4
    Endothelial pore formation causes rapid drop in transendothelial electrical resistance, loss of VE-cadherin junctions, and paracrine release of mature IL-1β and IL-18 [1][7].
  • 5
    Pharmacological targeting using NLRP3 ATPase inhibitors like MCC950 or Gasdermin D Cys191 covalent modifiers rescues microvascular barrier integrity [4][7][8].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit Doxorubicin 0.5 μM TWIK2 TLR4 GSDMD Pore K + NEK7 Mitochondria ROS ox-mtDNA IKK P IκBα NF-κB p65 / RelA NLRP3 ASC Caspase-1 GSDMD-N Asp275 Pyroptosis
Molecular Signaling Cascade of Doxorubicin-Triggered Endothelial Pyroptosis and Paracrine Cardiotoxicity.

The diagram displays a cardiac microvascular endothelial cell adjacent to a cardiomyocyte separated by an interstitial barrier. Within the endothelial cell, doxorubicin enters via passive and carrier-mediated transport, accumulating in mitochondria to stimulate NOX4/Complex I redox cycling, superoxide formation, and cardiolipin oxidation. Cytoplasmic ox-mtDNA triggers TLR4/NF-κB-dependent transcription of NLRP3 and pro-IL-1β (Signal 1), while TWIK2-mediated potassium efflux promotes NEK7-NLRP3-ASC speck nucleation (Signal 2), driving Caspase-1-mediated GSDMD cleavage, 10–14 nm plasma membrane pore assembly, and paracrine IL-1β leakage toward cardiomyocyte IL-1R1 receptors.

Endothelial Vulnerability Beyond Topoisomerase IIβ Target Engagement in Cardiomyocytes

Canonical mechanisms of anthracycline-induced cardiac dysfunction focus on doxorubicin-mediated poisoning of Topoisomerase IIβ in terminally differentiated myocytes [1]. This conventional focus presumes that double-strand DNA breaks and secondary necrosis initiate myocardial failure [2]. However, clinical reductions in left ventricular ejection fraction occur late, following extensive, irreversible myocardial architecture collapse [1][3]. Emerging multi-omic profiling reveals that cardiac microvascular endothelial cells (CMECs) suffer primary damage well before measurable troponin release appears in peripheral circulation [1]. CMECs in the primary human cardiac microvascular endothelial cell culture system display an acute vulnerability threshold when exposed to sub-micromolar doxorubicin concentrations between 0.2 and 1.0 μM [2]. In contrast to adult cardiomyocytes, which maintain compensatory catalase and glutathione peroxidase reserves, CMECs exhibit low baseline expression of hydrogen peroxide-detoxifying enzymes [1][3].

As summarized in Table 1, distinct pharmacokinetic thresholds, membrane dynamics, and inflammatory activation kinetics differentiate microvascular endothelial susceptibility from classic cardiomyocyte mechanical failure. Exposure to 0.5 μM doxorubicin induces pronounced upregulation of vascular cell adhesion molecule-1 (VCAM-1) in cardiac vascular beds within hours of administration [1]. This surface reprogramming promotes early granulocyte attachment and microvascular obstruction prior to global contractile decline [1][2]. In the C57BL/6J mouse model, systemic administration alters endothelial drug distribution and vascular permeability across capillary networks, disrupting local homeostasis [2][3]. The rapid onset of endothelial dysfunction establishes the cardiac microvasculature as the primary cellular target mediating progressive anthracycline cardiotoxicity [1][3].

Mitochondrial Redox Cycling and Priming of the NLRP3 Nucleation Complex

Intracellular uptake of doxorubicin across the endothelial plasma membrane leads to preferential accumulation within mitochondrial inner membranes [4][5]. The quinone moiety of the anthracycline core undergoes one-electron reduction catalyzed by mitochondrial Complex I (NADH dehydrogenase) and endothelial NADPH oxidases, specifically NOX4 [4]. This enzymatic reduction forms an unstable semiquinone radical intermediate [4][5]. Rapid auto-oxidation of the semiquinone regenerates the parent quinone compound while transferring electrons directly to molecular oxygen, generating a sustained efflux of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) [4]. Hydroxyl radical generation via trace-iron-dependent Fenton chemistry accelerates oxidative scission of cardiolipin, disrupting inner mitochondrial membrane potential (ΔΨ_m) [4][5].

Accumulating reactive oxygen species induce oxidative modifications on mitochondrial DNA, yielding 8-hydroxy-2'-deoxyguanosine-rich fragments (ox-mtDNA) that extrude through permeability transition pores into the endothelial cytosol [4][6]. Cytosolic ox-mtDNA engages Toll-like receptor 4 (TLR4) signaling networks, triggering IκB kinase activation and NF-κB p65 nuclear translocation [5][6]. This pathway represents Signal 1 priming, driving transcriptional expression of pro-IL-1β, pro-IL-18, and sensor protein NLRP3 [4][6]. Simultaneously, doxorubicin activates Signal 2 through cellular potassium efflux via TWIK2 two-pore domain potassium channels [4]. Intracellular K+ depletion facilitates structural binding between the non-catalytic domain of NIMA-related kinase 7 (NEK7) and the leucine-rich repeats of NLRP3 [4][6]. This direct interaction triggers conformational rearrangement of the NLRP3 central NACHT domain, exposing oligomerization interfaces essential for nucleation [4].

Caspase-1 Processing Kinetics and Gasdermin D Pore Architecture

Following NEK7 licensing, the pyrin domain (PYD) of nucleated NLRP3 recruits the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) via homotypic PYD-PYD interactions [6][7]. ASC nucleates into macroscopic helical filaments that coalesce into a solitary, dense supramolecular assembly termed the ASC speck [7]. The exposed caspase activation and recruitment domain (CARD) of assembled ASC binds the CARD motif of pro-Caspase-1 [7][8]. High local proximity induces intermolecular dimerization and auto-catalytic processing of the 45 kDa zymogen into active p20 and p10 subunits, forming the catalytically competent (p20/p10)2 heterotetramer [7]. Active Caspase-1 exhibits high catalytic efficiency toward Gasdermin D (GSDMD), executing site-specific endopeptidase cleavage at the Asp275 residue situated within the flexible interdomain linker [7][8].

Cleavage at Asp275 liberates the active 31 kDa GSDMD N-terminal domain (GSDMD-N) from its auto-inhibitory C-terminal regulatory domain [7][8]. In the AC16 human cardiomyocyte cell line and adjacent microvascular endothelium, doxorubicin exposure markedly increases GSDMD-N abundance [7][8]. Uncaged GSDMD-N exposes basic, amphipathic surface patches that bind phosphoinositides, specifically phosphatidylinositol 4,5-bisphosphate [PI(4,5)P₂] and phosphatidylserine, on the inner leaflet of the plasma membrane [7]. Membrane insertion drives oligomerization of 16 to 28 GSDMD-N protomers into an asymmetric, ring-shaped transmembrane barrel possessing an inner conduit diameter of 10 to 14 nm [8]. These stable conduits alter membrane permeability by permitting unhindered flux of water and ions down electrochemical gradients, resulting in rapid loss of cellular homeostasis [7][8].

Microvascular Permeability Collapse and Paracrine Myocardial Disruption

GSDMD conduit insertion rapidly dissipates transmembrane ionic gradients, triggering rapid intracellular sodium and water influx driven by cytoplasmic oncotic pressure [7][8]. The resulting cellular swelling culminates in plasma membrane rupture and the release of lactate dehydrogenase [7]. Concurrently, GSDMD pore formation initiates targeted endopeptidase-mediated disassembly of endothelial adherens junctions [1][3]. Immunofluorescence analysis of continuous endothelial monolayers confirms profound cleavage and internalization of vascular endothelial cadherin (VE-cadherin/CD144) alongside destabilization of zonula occludens-1 (ZO-1) tight-junction networks [1]. In vitro Transwell barrier assays using HCMECs establish that 0.5 μM doxorubicin causes a steep decline in transendothelial electrical resistance (TEER) within 12 hours, preceding structural injury in co-cultured myocytes [1][3].

Membrane disruption enables immediate, uncontrolled extrusion of mature IL-1β (17 kDa) and IL-18, processed by Caspase-1 from their immature pro-forms [7][8]. In the Sprague-Dawley rat model, anthracycline treatment generates high local concentrations of mature IL-1β in cardiac interstitial spaces [1][5]. Released IL-1β engages the type I interleukin-1 receptor (IL-1R1) on neighboring myocytes, initiating MyD88-dependent signal cascades that promote calcineurin activation and NFAT dephosphorylation [5][6]. This paracrine signaling axis suppresses sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) expression, impairing calcium reuptake during diastole [1][8]. Furthermore, unbuffered microvascular barrier breakdown facilitates unrestricted extravasation of circulating anthracyclines directly into the myocardial parenchymal space, compounding myocyte toxicity [1][2].

Therapeutic Intervention Nodes: Direct Inhibitors of Inflammasome Components

Elucidation of the endothelial pyroptotic pathway reveals targeted intervention opportunities to mitigate anthracycline cardiotoxicity without blunting oncological efficacy [4][7]. Direct pharmacological inhibition of the NLRP3 sensor represents an effective upstream strategy [4][6]. Small-molecule inhibitors MCC950 (CRID3) and dapansutrile (OLT1177) bind the ATP-hydrolysis site within the NACHT domain of NLRP3 with high affinity (IC50 ~ 7.5 nM for MCC950) [4]. These agents lock the sensor in an inactive, closed conformation, blocking ATP hydrolysis, NEK7 recruitment, and ASC speck oligomerization [4][6]. In H9c2 rat myoblast cell line cultures and primary microvascular endothelial models, pre-treatment with MCC950 blocks doxorubicin-induced Caspase-1 activation and suppresses IL-1β release [4][7].

Interventions targeting downstream pore execution provide alternative cytoprotection [7][8]. Disulfiram, an FDA-approved compound repurposed as an anti-pyroptotic agent, covalently modifies Cys191 on human GSDMD (Cys192 in rodents) via dithiocarbamylation [7]. This modification prevents GSDMD-N protomers from inserting into the plasma membrane without impairing upstream Caspase-1 maturation [7][8]. Similarly, necrosulfonamide binds GSDMD directly, halting functional pore assembly [8]. Upstream redox interception also limits inflammasome priming [4][6]. Mitochondria-targeted antioxidants, such as MitoTEMPO, selectively scavenge mitochondrial superoxide, suppressing ox-mtDNA formation [4]. Although the systemic iron chelator dexrazoxane remains the sole clinically approved cardioprotective agent for anthracyclines, its activity stems from Topoisomerase IIβ catalytic modulation and iron chelation [4][7]. Combining dexrazoxane with targeted NLRP3 or GSDMD inhibitors presents a synergistic paradigm to protect both the microvascular endothelium and contractile cardiomyocytes against doxorubicin-mediated damage [4][7][8].

Table 1. Comparative Mechanistic and Pharmacological Vulnerability Profiles of Cardiac Cell Types Exposed to Doxorubicin

Biological & Pharmacological ParameterCardiac Microvascular Endothelium (CMEC)Adult Ventricular CardiomyocyteCardiac FibroblastTranslational Significance
Primary Cytotoxic Trigger Concentration0.2–0.5 μM1.0–2.5 μM> 5.0 μMMicrovasculature sustains structural damage at lower anthracycline thresholds
Dominant Cell Death ModalityPyroptosis (GSDMD-dependent)Apoptosis & Secondary Necrosis (Top2β)Senescence & Phenotypic ActivationInflammasome pore formation drives early microvascular permeability breakdown
Detoxifying Enzyme Profile (Catalase/GPX)Markedly LowModerate to HighHighEndothelial cells fail to clear mitochondrial superoxide and hydrogen peroxide
Membrane Permeability Kinetics (t1/2)4–8 hours18–24 hours> 36 hoursEndothelial barrier collapse precedes measurable troponin leakage
Key Secreted Inflammatory MediatorsMature IL-1β (17 kDa), IL-18, VCAM-1Troponin I/T, CK-MB, Natriuretic PeptidesTGF-β1, Collagen Type I/IIIEndothelial cytokines trigger adverse paracrine remodeling in myocytes
Established Pharmacological Rescue NodeNLRP3 (MCC950) / GSDMD (Disulfiram)Dexrazoxane (Top2β clearance)Pirfenidone / ALK5 InhibitorsDual microvascular and myocyte protection requires distinct target engagement

Note: Table 1 compares empirical vulnerability parameters between microvascular endothelial cells, cardiomyocytes, and fibroblasts under anthracycline challenge, emphasizing the heightened sensitivity of endothelial beds.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

Why do cardiac microvascular endothelial cells exhibit higher sensitivity to doxorubicin than ventricular cardiomyocytes?Experimental Model Selection

Microvascular endothelial cells possess significantly lower baseline expression of key endogenous antioxidant enzymes, such as catalase and glutathione peroxidase, compared to mature cardiomyocytes [1][3]. Following doxorubicin exposure, mitochondrial redox cycling produces high concentrations of superoxide anions and cardiolipin-directed peroxidation products that endothelial cells cannot neutralize efficiently [3][4]. Furthermore, endothelial cells rapidly upregulate VCAM-1 and undergo TWIK2-mediated potassium efflux, lowering the activation threshold for NLRP3 inflammasome nucleation and GSDMD-dependent pyroptosis at sub-micromolar drug levels (0.2–0.5 μM) [1][2].

How can researchers verify Gasdermin D cleavage versus apoptotic Caspase-3 signaling in vitro?Assay Optimization & Validation

Discriminating pyroptosis from classical apoptosis requires tracking specific proteolytic fragments and pore kinetics [5][6]. Western blotting should resolve the distinct 31 kDa GSDMD-N cleaved fragment on high-percentage (12–15%) SDS-PAGE gels, alongside the Caspase-1 p20 subunit, rather than the 17/19 kDa cleaved Caspase-3 products [7][8]. In addition, dual kinetic fluorescence microscopy using cell-impermeable dyes such as SYTOX Green paired with Hoechst 33342 demonstrates rapid membrane conduit formation (within 2 to 4 hours) in pyroptotic cells, in contrast to the late membrane compromise characteristic of secondary apoptotic necrosis [1][8].

What concentrations of MCC950 and disulfiram are recommended for suppressing endothelial pyroptosis in cardiac co-cultures?Pharmacological In Vitro Screening

In co-culture and monoculture bioassays using human cardiac microvascular endothelial cells, MCC950 effectively inhibits the NLRP3 NACHT domain ATPase activity at working concentrations of 1 to 10 μM (in vitro IC50 ~ 7.5 nM), added 1 hour prior to doxorubicin administration [4][6]. For GSDMD pore inhibition, disulfiram should be dosed between 5 and 20 μM to ensure covalent dithiocarbamylation of Cys191 without provoking off-target cellular toxicity [7][8]. These dosing windows successfully block active IL-1β secretion and preserve transendothelial electrical resistance across cellular monolayers [1][7].

References

  1. [1]. Zhang J, et al. Advanced Healthcare Materials. 2026;15(16). [IF: 9.6]
  2. [2]. Ji H, et al. Experimental & Molecular Medicine. 2025;57(1):249-263.
  3. [3]. Norton N, et al. Frontiers in Cardiovascular Medicine. 2020;7. [IF: 6.05]
  4. [4]. Zeng H, et al. Cardiovascular Diagnosis and Therapy. 2024;14(1):84-100. [IF: 2.1]
  5. [5]. Sumneang N, et al. Molecules. 2023;28(11):4294.
  6. [6]. Zhu P, et al. Frontiers in Cardiovascular Medicine. 2024;11. [IF: 2.9]
  7. [7]. Zhang G, et al. Oxidative Medicine and Cellular Longevity. 2022;2022(1). [IF: 7.31]
  8. [8]. Wang Z, et al. Cell Death Discovery. 2025;11(1). [IF: 7.0]